Margreet A. Veening

Veldhoven, NB, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Oncofertility care evaluation of 599 children and adolescents with cancer and a high risk of treatment-induced gonadal damage: a national paediatric oncology cohort study.

Oncofertility care evaluation of 599 children and adolescents with cancer and a high risk of treatment-induced gonadal damage: a national paediatric oncology cohort study.

Journal: Human reproduction (Oxford, England)

Published: April 15, 2026

Action for first-line PD-1 inhibitors in paediatric Hodgkin lymphoma.

Action for first-line PD-1 inhibitors in paediatric Hodgkin lymphoma.

Journal: Lancet (London, England)

Published: November 14, 2025

Safety of laparoscopic oophorectomy in a Dutch national pediatric cancer cohort.

Safety of laparoscopic oophorectomy in a Dutch national pediatric cancer cohort.

Journal: F&S reports

Published: September 18, 2025

Nephrotoxicity Surveillance for Childhood and Young Adult Survivors of Cancer: Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Nephrotoxicity Surveillance for Childhood and Young Adult Survivors of Cancer: Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 20, 2025

Fertility-Preserving Treatments and Patient- and Parental Satisfaction on Fertility Counseling in a Cohort of Newly Diagnosed Boys and Girls with Childhood Hodgkin Lymphoma.

Fertility-Preserving Treatments and Patient- and Parental Satisfaction on Fertility Counseling in a Cohort of Newly Diagnosed Boys and Girls with Childhood Hodgkin Lymphoma.

Journal: Cancers

Published: April 25, 2024

NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: A high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker.

NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: A high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker.

Journal: HemaSphere

Published: April 08, 2024

Immunoglobulin prophylaxis prevents hospital admissions for fever in pediatric acute lymphoblastic leukemia: results of a multicenter randomized trial.

Immunoglobulin prophylaxis prevents hospital admissions for fever in pediatric acute lymphoblastic leukemia: results of a multicenter randomized trial.

Journal: Haematologica

Published: March 08, 2024

Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol.

Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol.

Journal: Human reproduction (Oxford, England)

Published: March 03, 2024

Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.

Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 02, 2024

The impact of treatment for childhood classical Hodgkin lymphoma according to the EuroNet-PHL-C2 protocol on serum anti-Müllerian Hormone.

The impact of treatment for childhood classical Hodgkin lymphoma according to the EuroNet-PHL-C2 protocol on serum anti-Müllerian Hormone.

Journal: Human reproduction (Oxford, England)

Published: December 12, 2023

Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups.

Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 17, 2023

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.

Journal: Frontiers in immunology

Published: May 26, 2023

Showing 1-12 of 49

Last Updated: 09/26/2026